NCT06974812View on ClinicalTrials.gov

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Unresectable Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

IBI3014

12 mg/kg D1 IV Q3W

DRUG

IBI3014

6 mg/kg D1 IV Q3W

DRUG

IBI3014

1 mg/kg D1 IV Q3W

DRUG

IBI3014

15 mg/kg D1 IV Q3W

DRUG

IBI3014

9 mg/kg D1 IV Q3W

DRUG

IBI3014

3 mg/kg D1 IV Q3W

Trial Locations (1)

350014

RECRUITING

Fujian cancer hospital, Fuzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06974812 - IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter